Keros Therapeutics (KROS) is a clinical-stage biopharmaceutical company. George Tsilis discusses KROS as the company focuses on developing treatments for hematological and musculoskeletal disorders. He talks about how KROS presented data from ongoing Phase 2 clinical trials of Ker-050 and Ker-047 at a healthcare conference. Tune in to find out more about the stock market today.
14 Dec 2022
Market On Close
23 Jan 2023
Morning Trade Live
14 Nov 2022
The Watch List
09 Dec 2022
The Watch List
31 Jan 2023
The Watch List
22 Jan 2023